In our second anniversary special, hear from Visiopharm CEO and founder Michael Grunkin. Digital pathology, with regulatory approvals for whole slide imaging, aims to increase precision & productivity in pathology labs. However, slow adoption is due to high investment costs beyond just the scanner. Image analysis and AI hold higher value for pathology, but standardization of tissue diagnostic assays is still lacking. Only fully digital pathology institutions benefit, but incremental adoption could increase adoption & value for all. Learn more in the episode and from Visiopharm’s contributions to digital transformation in pathology.

• Let us know what you think of the episode and any topics you would like us to cover in the future by sending us an email at: podcasts@visiopharm.com